Watchdog Asks HHS Inspector General to Investigate FDA Peptide Panel's Financial Conflicts

The Campaign Legal Center has escalated the fight over the FDA's July 23-24 peptide advisory meeting, sending a letter to HHS Inspector General T. March Bell asking his office to investigate whether committee members broke federal ethics law.

The letter, sent last week and first reported by the Washington Post, targets the FDA's Office of Ethics and Integrity directly. According to Kedric Payne, the group's vice president and general counsel, and Margaret Dylus-Yukins, its senior legal counsel for ethics, the FDA's ethics office found zero conflicts of interest among the 2026 Pharmacy Compounding Advisory Committee members, despite what they describe as clear public evidence to the contrary.

Payne and Dylus-Yukins say at least seven committee members had financial interests in the peptide or pharmaceutical industries at the time of the vote. They name Dr. Asare Christian, founder of a longevity clinic that advertises two of the peptides under review, and Dr. Gabriel Alizaidy, scientific director of Maximus Health, an online peptide pharmacy whose website ran articles about FDA oversight of the industry without disclosing Alizaidy sat on the panel deciding that oversight.

The Campaign Legal Center wants HHS OIG to determine whether panelists violated criminal conflict-of-interest statutes by participating without ethics waivers in place.

What the panel actually voted for

This traces back to the two-day meeting where the committee reviewed seven peptides for possible addition to the FDA's list of substances legal for pharmacy compounding. The panel recommended six: BPC-157, KPV, TB-500, MOTS-c, epitalon, and semax. It voted down only one, emideltide, by a 7-6 margin, according to MedPage Today. Every affirmative vote landed in a tight 7-6 or 8-6 range.

The Washington Examiner's Peter Pitts, a former FDA associate commissioner writing under his own byline, called that pattern itself suspicious. "A scientific committee applying a consistent evidentiary standard to seven substances supported by widely varying data should not produce a succession of nearly identical cliffhangers," he wrote, arguing the uniform margins point to a bloc of votes driven by something other than case-by-case review of evidence.

FDA career scientists reviewed all seven peptides ahead of the meeting and recommended against listing every single one, citing a lack of credible safety and efficacy data, according to the Associated Press, as carried by Breitbart. The panel overruled its own agency's scientists six times out of seven.

Dr. Peter Lurie, a former FDA associate commissioner who now runs the Center for Science in the Public Interest, called the episode "an extraordinary abuse of the advisory committee process to secure ends that have no basis in science," according to the Washington Examiner.

The other side of the argument

Not every panelist who voted yes has an obvious financial stake, and the "yes" votes weren't purely industry insiders rubber-stamping a foregone conclusion. David Pope, chief pharmacy officer of Xifin Pharmacy Solutions, framed his vote as a matter of patient autonomy rather than industry payoff. "I voted yes because it's time to put this decision back in the hands of the patient, the physician and the pharmacist," he said after the BPC-157 vote, according to the Associated Press.

That's a legitimate position separate from conflict-of-interest questions. Many patients are already buying these peptides through gray-market and online channels regardless of what the FDA decides, and proponents argue formal compounding oversight would at least bring manufacturing standards into the light. Forbes noted that millions of people are already self-administering peptides based on social media advice rather than physician guidance, a dynamic that exists whether or not the FDA changes the compounding list.

Dr. Elizabeth Rebello of the University of Texas MD Anderson Center, who voted no, put her finger on the tension driving the whole debate. "I'm concerned we're responding to a market-induced demand rather than a decision based in solid science," she said, according to the Associated Press.

No waivers, HHS says nothing wrong happened

HHS's response to the broader conflict-of-interest criticism has been that all panel members went through the standard ethics review, according to the Washington Examiner. That's a description of a process, not a rebuttal of the specific financial ties the Campaign Legal Center laid out by name. No investigation has been announced by HHS OIG as of this writing. No charges have been filed against any panelist. The Campaign Legal Center's letter contains allegations, not proven violations.

What happens next

The FDA is not legally required to follow PCAC's recommendations, but historically it almost always does, according to NPR. Ilisa Bernstein, a former FDA official, said the agency "needs to follow the data" regardless of political pressure. Jesse Dresser, an attorney who represents compounding pharmacies, told NPR he'd be surprised if the FDA used the traditional, slower rulemaking process at all, predicting the agency will instead lean on faster mechanisms like placing the peptides on the interim "Category One list" to let compounding pharmacies start production sooner.

Five additional peptides are scheduled for review when PCAC reconvenes in early 2027. Whether HHS OIG opens a formal investigation into this year's panel, and whether the FDA moves to finalize the six peptide recommendations before that question is resolved, remain open.